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The majority of the 150 currently available hydro-cephalus valves, as well as the much smaller selec-tion of the frequently used versions, are based on 
differential pressure technology. In vitro these valves share 
a predisposition to overdrainage in the vertical position12 
despite improvements such as adjustability and so-called 
flow control. The clinical relevance of this predisposition 
remains a controversial subject because all hypotheses 
seem to be compromised by a general lack of clearly de-
fined clinical data pertaining to overdrainage and its seque-
lae.7,17,18 Laboratory tests of shunt systems conducted in 
Germany by Aschoff and others2,6 along with accumulated 
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Object. Over the past decade, a gravity-assisted valve (GAV) has become a standard device in many European 
pediatric hydrocephalus centers. Because past comparative clinical outcome studies on valve design have not in-
cluded any GAV, the authors in this trial evaluated the early results of GAV applications in a pediatric population.
Methods. For a minimum of 2 years the authors monitored 169 of 182 hydrocephalic children who received a 
pediatric GAV at their first CSF shunt insertion (61.5%) or as a substitute for any differential pressure valve (38.5%) 
at 1 of 7 European pediatric hydrocephalus centers. Outcomes were categorized as valve survival (primary outcome) 
or shunt survival (secondary outcome). The end point was defined as valve explantation.
Results. Within a follow-up period of 2 years, the valve remained functional in 130 (76.9%) of 169 patients. One 
hundred eight of these patients (63.9%) had an uncomplicated clinical course without any subsequent surgery, and 22 
(13%) were submitted to a valve-preserving catheter revision without any further complications during the follow-
up period. Thirty-nine patients (23.1%) reached an end point of valve explantation: 13 valve failures from infection 
(7.7%), 8 (4.7%) from overdrainage, and 18 (10.6%) from underdrainage.
Conclusions. Compared with nongravitational shunt designs, a GAV does not substantially affect the early com-
plication rate. Valve-preserving shunt revisions do not increase the risk of subsequent valve failure and therefore 
should not be defined as an end point in studies on valve design. A significant impact of any well-established valve 
design on the early complication rate in shunt surgery is not supported by any current data; therefore, this correlation 
should be dismissed. As overdrainage-related complications have been shown to occur late, the presumed advantages 
of a pediatric GAV remain to be shown in a long-term study. (DOI: 10.3171/2009.4.PEDS08204)
KEy WorDs      •      hydrocephalus      •      children      •      shunt      •      complication      •       
cerebrospinal fluid      •      gravity-assisted valve
Abbreviation used in this paper: GAV = gravity-assisted valve.
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clinical experience with overdrainage-induced problems 
have directed increased attention to the early signs and 
previously underestimated late adverse effects of chronic 
overdrainage. This shift in expert awareness has advanced 
the development of a contemporary version of the GAV for 
pediatric patients. To date, only single-center results have 
been published.3,9,10,14 Because major comparative studies 
on valve design8 have not been focused on any GAV, we 
conducted a complementary trial on a pediatric GAV.
Methods
Study Eligibility
Patients up to the age of 16 years who were scheduled 
to receive a pediatric GAV (paediGAV, B Braun/Aesculap) 
for the first time were eligible to participate in this prospec-
tive study. Indications for a GAV were 1) newly diagnosed 
hydrocephalus with documented cerebral ventriculomega-
ly requiring CSF shunt insertion, or 2) documented shunt 
malfunction due to obstruction or overdrainage or follow-
ing shunt infection in patients with a standard differential 
pressure valve. This approach is the standard therapeutic 
procedure at the 7 European centers participating in the 
study, and written parental consent was obtained in every 
case. In discussions, the local ethics committees confirmed 
that their approval was not necessary for the study to pro-
ceed.
Patients were excluded if they exhibited an active CSF 
infection, any systemic disorder precluding CSF diversion, 
or septated ventricular loculations requiring > 1 ventricular 
catheter. Patients who did not attend follow-up examinations 
or who died < 3 months after shunt placement for reasons 
unrelated to hydrocephalus or to the shunt were also exclud-
ed. Patients who did not attend the final follow-up examina-
tion or who died of non–shunt-related causes > 3 months af-
ter shunt placement were classified as dropouts. Since these 
patients did not demonstrate any demographic or etiological 
differences from the study group, they were entered into the 
database and included in the statistical analysis.
Patient Population
One hundred eighty-two patients were enrolled be-
tween January 2003 and January 2005. They received a 
pediatric GAV for the first time during an initial shunt 
procedure (61.5%) or as a substitute for any standard dif-
ferential pressure valve (38.5%). Initial shunt procedures 
were performed in 83 (96.5%) of 86 children < 1 year of 
age and in 21 (25%) of 83 children ≥ 1 year of age. Thir-
teen of 182 initially enrolled patients were excluded from 
the study because they were continuously inaccessible for 
follow-up (8 patients) or because they died < 3 months af-
ter shunt placement for reasons unrelated to hydrocepha-
lus or the shunt (5 patients). The baseline characteristics 
of the remaining 169 patients are shown in Tables 1 and 
2. There were 71 female (42%) and 98 male (58%) patients 
with an age range from newborn to 16 years. The mean 
age was 4.3 years, with a median of 0.93 year. 
Treatment Protocol
Each patient received a GAV (Fig. 1) combining 1 of 
2 levels of the opening pressure of the differential pres-
sure components (4 or 9 cm H2O) with 1 of 4 levels of 
the opening pressure of the gravitational component (14, 
19, 24, or 29 cm H2O). Available fixed settings were (in 
cm H2O) 4/14, 4/19, 4/24, 9/19, 9/24, or 9/29. The manu-facturer’s recommendations for the optimal valve settings 
are 4/24 (≤ 6 months of age), 9/24 (6 months to 5 years of 
age), and 9/29 cm H2O (> 5 years of age). The indication for surgery, extent of hair removal, site of shunt insertion, 
valve setting, surgical technique, perioperative medication, 
and subsequent treatment of shunt malfunction were left 
to the regulations of each participating center, because we 
wanted the results to reflect everyday hospital situations.
Follow-Up Monitoring
Patients were to complete a perioperative assessment 
and a follow-up at 3, 6, 12, and 24 months after surgery. In 
TABLE 1: Age distribution of 169 patients with hydrocephalus
Age (yrs) No. of Patients No. Preterm (%)
0 to <1 86 42
1 to <2 8 2
2 to <4 13 3
4 to <6 10 2
6 to <8 6 1
8 to <10 9 3
10 to <12 10 3
12 to <14 18 4
14 to 16 9 1
total 169 61 (36.1)
TABLE 2: Cause of hydrocephalus in 169 patients
Disorder No. of Cases (%)
hemorrhage 51 (30.2)
dysraphic malformation 40 (23.7)
 Chiari malformation 15
 Dandy-Walker malformation 5
 no specification 20
nondysraphic malformation 14 (8.3)
 arachnoid cyst 5
 connatal aqueductal stenosis 3
 angioma 1
 schizencephaly 3
 Walker-Warburg syndrome 1








 no specification 10
head injury 3 (1.8)
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cases of subsequent valve-preserving procedures within 
the follow-up period, another perioperative assessment 
was added for each intervention. If the end point of valve 
explantation was reached, the type and site of shunt mal-
function were recorded. A record of each assessment was 
sent to the study office and checked for completeness by 
the study nurse. A copy was sent to the study headquar-
ters and reviewed by an independent physician not be-
longing to the paediGAV study group.
Primary and Secondary Outcomes
The end point in this study was valve explantation due 
to overdrainage, underdrainage, or infection. The primary 
outcome category was valve survival even if it involved any 
type of shunt malfunction treated with a valve-preserving 
procedure, the loss of a patient from the study because of a 
non–shunt related death after at least 1 completed follow-
up assessment, and surgical complications preserving all 
parts of the shunt. The secondary outcome category was 
shunt survival without any surgery after implantation.
Statistical Analysis
Follow-up was submitted to consistent criteria. Patient 
age was not corrected for the separate variable of prema-
turity. Patient-related variables assessed for their effect on 
valve and shunt survival included disease origin, gestation 
age, age at the time of shunting, and first shunt implanta-
tion versus valve exchange. The only surgeon-controlled 
variable was the valve setting. Fragmentary information—
attributable to the participating centers’ different diagnos-
tic approaches to head circumference, radiological exami-
nations, and frontal/occipital horn ratio—was entered into 
the database but was not submitted to statistical analysis. 
For categorical data, absolute and proportional frequencies 
were given. Metrical variables were described as the means 
± SDs, medians, and ranges (minimum and maximum). In 
the case of categorical data, group comparisons were made 
using the chi-square and Fisher exact test when appropri-
ate. Since normality for all metrical variables cannot be as-
sumed, the Mann-Whitney U-test was used for comparison 
of the 2 groups, and the Wilcoxon test was used for paired 
samples. Age and pressure were respectively dichotomized 
as < versus ≥ 1 year of age and as ≤ 4/24 versus ≥ 9/19 cm 
H2O. Survival analyses with respect to age, and de novo implantation versus revision were conducted using Kaplan-
Meier curves. For the respective confirmative analyses, the 
log-rank test and Cox regression models were used. The 
level of significance was α = 0.05 (2-tailed). No adjustment 
of the α level was made for multiple testing (Bonferroni 
correction) because of the exploratory nature of the study.
Results
None of the etiological factors (Table 2) were associ-
ated with the frequency of underdrainage, overdrainage, 
infection, or any other outcome event (p > 0.005, chi-
square test). The median follow-up among 169 patients, 
including those who reached the end point of valve ex-
plantation, was 21.8 months. Thirty-two patients (18.9%) 
with a median follow-up of 12 months were classified as 
dropouts; 6 of them (3.5%) died > 3 months after shunt 
placement for non–shunt-related reasons, and 26 (15.4%) 
did not attend the final follow-up examination. The drop-
out group showed no demographic or etiological differ-
ences from the study group (Wilcoxon test).
Valve Setting
The pattern of the choice of opening pressure (PO) set-
tings differed largely across the participating centers. The 
overall distribution of valve settings is shown in Fig. 2. 
With regard to the opening pressure of the ball in the conus 
component (PO = 4 or 9 cm H2O), the higher PO was chosen 
in 76% of cases. Low-opening-pressure valves were pre-
dominantly used in the younger age group (Fig. 3). Valve 
setting was not associated with the frequency of infection, 
overdrainage, or underdrainage (p > 0.005, chi-square test). 
Provided the described choice pattern, the different valve 
settings did not correlate with shunt or valve survival.
Fig. 1. A: Schematic showing the paediGAV construction in the hori-
zontal position. The ball in the closed conus compartment (normal ICP) 
and the gravitational compartment contributing no additional resistance 
(upper). Ball in the open conus compartment (ICP < 9 cm H2O), with the 
gravitational compartment open and contributing no additional resis-
tance (lower): ICP > (9 + 0 =) 9 cm H2O. B: Schematic showing the 
paediGAV construction in the vertical position. The ball is in the closed 
conus compartment (ICP < 9 cm H2O), and the gravitational compart-
ment is closed, contributing full gravitational resistance of 20 cm H2O 
(left). The ball is in the open conus compartment (ICP > 9 cm H2O), with 
the gravitational compartment contributing full gravitational resistance 
(here: 20 cm H2O) and open (right): ICP > (9 + 20 =) 29 cm H2O.
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Early Complications
The most frequent reason for a surgical revision dur-
ing the follow-up period was underdrainage in 28 chil-
dren (16.5%)—due to proximal catheter obstruction in 
17 (10.0%), valve obstruction in 8 (4.7%), and distal cath-
eter obstruction in 3 (1.8%)—followed by infection in 11 
(6.5%) and overdrainage in 8 (4.7%; Table 3).
Shunt and Valve Survival
The rate of overall shunt survival was 72.6 and 62.0% 
at 1 and 2 years after shunt insertion, respectively (Fig. 4). 
The rate of overall valve survival was 79.2 and 75.6% at 1 
and 2 years, respectively (Fig. 5). Age at surgery showed 
an insignificant trend toward better results in children older 
than 1 year in terms of both shunt survival (80.0 vs 65.6% 
at 1 year and 66.9 vs 57.4% at 2 years after shunt inser-
tion) and valve survival (86.2 vs 72.4% at 1 year and 80.3 
vs 71.1% at 2 years after shunt insertion). Compared with 
a primary shunt insertion, a valve exchange showed an 
insignificant trend toward better results in terms of shunt 
survival (75.2% for valve exchange vs 71.2% for primary 
insertion after 12 months and 64.9 vs 60.3%, respectively, 
after 24 months) as well as valve survival (82.9 vs 77.0% 
at 1 year and 79.6 vs 73.0% at 2 years, respectively). These 
variables were not independent given that a younger age 
correlated with primary shunt insertion, and an older age 
with valve exchange.
Repeated Operations
The average interval between shunt surgery and re-
operation was 0.8 months for infection, 2.8 months for 
obstruction, and 10.9 months for overdrainage. Seventy-
six percent of all reoperations and 89% of all valve ex-
plantations were performed within 12 months after the 
initial surgery. The risk of surgery declined by 50% every 
6 months for the first 2 years after surgery. Valve-preserv-
ing operations carried a small risk of subsequent valve 
explantation only if they were performed earlier than 3 
months after the initial shunt placement. After this inter-
val they had no impact whatsoever on valve survival. The 
Fig. 2. Bar graph demonstrating the frequency with which a valve was chosen. Frequency refers to the number of cases. Data 
in 2 patients could not be verified; therefore, the graph represents data in 167 patients.
Fig. 3. Bar graph revealing the age-dependent choice of valve pressure setting.
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overall risk of valve explantation after a valve preserving 
operation was not increased in comparison with the risk 
in patients who did not undergo any repeat operative pro-
cedures (77.2 vs 75.3%).
Discussion
In 1998 Drake et al.8 did not find significant differences 
in shunt survival among 3 common valve designs: a stan-
dard differential pressure valve, an adjustable differential 
pressure valve, and a so-called flow-controlled valve. Using 
comparable criteria, our results with the GAV did not dif-
fer significantly in terms of overall shunt survival. Taking 
into account some methodological differences, the similar-
ity of the results in both studies—independent of both the 
substantially different design of all the analyzed valves and 
the circumstances of investigation—remains striking and 
provides reasonable doubt as to whether valve features can 
be assessed based on the early results of shunt procedures. 
Shunt and valve survival in the first 2 years after insertion 
seems to be determined predominantly by the constantly 
high rate of early complications, which may be a function 
of how and in whom surgery is performed rather than of a 
particular valve design. Regarding the most common early 
complications, it has already been shown that shunt infec-
tions are related to a number of defined surgical and logis-
tic criteria.4,5 The high rate of mechanical complications 
may very well be associated with a high rate of ventricu-
lar catheter misplacement related to unguided insertion. 
Furthermore, the dynamic change in proportions between 
brain volume, head size, and ventricular volume in the first 
12–24 months in children younger than 1 year of age at the 
time of shunt insertion does make the proximal catheter 
the most vulnerable part of the shunt system, and thus the 
resulting migration and occlusion become the most com-
mon reasons—13.6% in our series—for early shunt failure. 
These factors are independent of shunt design. We found 
a small but persistent proportion of collapsed ventricles 
after shunt surgery despite the use of gravitational valves. 
Apart from the critical consideration of the correct surgi-
cal placement of the GAV—oblique positioning at surgery 
can permanently increase CSF drainage16—the available 
fixed pressure settings of the valve may not correspond ad-
equately to the hydrostatic needs of a child. Whether fac-
tors other than hydrostatic pressure (for example, the time 
course of elevated intracranial and intraabdominal pressure 
during crying or coughing) can contribute to overdrainage 
remains unknown. In contrast to other trial designs, we 
continued our follow-up after valve-preserving operations. 
The low impact of the replacement of ventricular or ab-
dominal catheters on the risk of subsequent valve explan-
tation supports the assumption that the majority of early 
shunt problems seem to be independent of valve features. 
Exceptions may be the proven associations between cath-
eter blockage and high-resistance valves11 and the signifi-
cant overdrainage related to the choice of inadequate shunt 
systems or incorrectly positioned valves.6 Nonphysiologi-
cal CSF diversion associated with chronic overdrainage 
and leading to a nonphysiological, low intracranial pres-
sure may be compensated for by the child for a long time 
while creating irreversible morphological and hemody-
namic consequences during this clinically “silent” period. 
Again, the findings of Drake and coworkers,8 as well as our 
study data revealing no differences in early results despite 
TABLE 3: Reasons for revision among 169 patients
Cases (%)
Reason for Op 1st Op Per Patient Total No. Ops 
underdrainage
  proximal catheter obstruction 17 (10.0) 20 (11.8)
  valve obstruction 8 (4.7) 8 (4.7)
  distal catheter obstruction 3 (1.8) 8 (4.7)
infection 11 (6.5) 13 (7.7)
overdrainage 8 (4.7) 8 (4.7)
unknown 8 (4.7) 8 (4.7)
catheter obstruction 6 (3.6) 9 (5.3)
total 61 74
Fig. 4. Kaplan-Meier curve depicting long-term shunt survival.
Fig. 5. Kaplan-Meier curve indicating long-term valve survival.
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the use of substantially different valve designs, support the 
assumption that a poor valve design can remain undetected 
during this early, clinically silent period. Returning years 
later for chronic headaches, a significant number of these 
initially symptom-free children frequently exhibit an irre-
versible slit ventricle syndrome.19 We believe that regarding 
the clinical impact of a valve design, attention must be fo-
cused on the long-term effects. Avoiding irreversible long-
term sequelae would also enable the justification of current 
considerable cost differences among the large variety of 
valve designs and additional components.
The true hope behind advancing valve designs is to 
improve the psychosocial development and quality of life 
in hydrocephalic children. As most of the relevant criteria 
can be assessed only at the ages of 5–6 years,13 there are 
no current data confirming the effects of any given valve 
design. At the same time and for the same reasons, the rel-
evance of shunt-related morphological changes, which can 
be assessed much earlier, remains unknown for the des-
tiny of patients. We therefore conclude that probably the 
only effective way to determine the impact of valve prop-
erties on the developing nervous system in hydrocephalic 
children will be to establish long-term protocols initially 
monitoring morphological data, such as ventricular dimen-
sions and skull properties, progressively extending to an 
assessment of intracranial brain and CSF volumes and late 
complication rates, and, once the child reaches the age of 
5–6 years, considering aspects pertaining to quality of life 
and psychosocial development.
Conclusions
Compared with other shunt designs, the use of a pedi-
atric GAV does not significantly affect the early compli-
cation rate in children. Valve-preserving shunt revisions 
do not increase the risk of subsequent valve failure. A 
significant impact of valve design on the early complica-
tion rate in shunt surgery is not supported by current data; 
therefore, we suggest using long-term protocols that focus 
on quality-of-life aspects and late complication rates and 
monitoring morphological data such as intracranial brain 
and CSF volumes and skull properties to describe the im-
pact of valve features on the developing nervous system 
in hydrocephalic children. The expected superior clinical 
performance of paediGAV, which to date has only been 
revealed in laboratory tests,1,15 remains to be demonstrat-
ed in just such a long-term study.
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